Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.

doi:10.1182/bloodadvances.2022007496

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.

Blood advances - 24 Jan 2023

Barnell Erica K, Skidmore Zachary L, Newcomer Kenneth F, Chavez Monique, Campbell Katie M, Cotto Kelsy C, Spies Nicholas C, Ruzinova Marianna B, Wang Tianjiao, Abro Brooj, Kreisel Friederike, Parikh Bijal A, Duncavage Eric J, Frater John L, Lee Yi-Shan, Hassan Anjum, King Justin A, Kohnen Daniel R, Fiala Mark A, Welch John S, Uy Geoffrey L, Vij Kiran, Vij Ravi, Griffith Malachi, Griffith Obi L, Wartman Lukas D

Abstract excerpt

Patients with multiple myeloma (MM) who are treated with lenalidomide rarely develop a secondary B-cell acute lymphoblastic leukemia (B-ALL). The clonal and biological relationship between these sequential malignancies is not yet clear. We identified 17 patients with MM treated with lenalidomide, who subsequently developed B-ALL. Patient samples were evaluated through sequencing, cytogenetics/fluorescence in situ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Burkitt Lymphoma

Share to Immunoglobulin Heavy Chains

Share to In Situ Hybridization, Fluorescence

Share to Lenalidomide

Share to Multiple Myeloma

Share to Mutation

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Source

Open in PubMed Open full text

Identifiers

PMID: 36251745
DOI: 10.1182/bloodadvances.2022007496
PMCID: PMC9860439

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.PMID 36251745Read ↗

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myelomaSemantic proximity Read ↗

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical ImplicationsSemantic proximity Read ↗

IDH2 clonal hematopoiesis and IKAROS loss cooperate in a B-ALL subtype after lenalidomide therapy for multiple myeloma.Semantic proximity Read ↗

Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple MyelomaSemantic proximity Read ↗

Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic ImplicationsSemantic proximity Read ↗

Clonal Evolution in Multiple Myeloma.Semantic proximity Read ↗

A systematic literature review on clonal evolution events preceding relapse in multiple myeloma.Semantic proximity Read ↗

Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma.Semantic proximity Read ↗

Molecular basis of clonal evolution in multiple myeloma.Semantic proximity Read ↗

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.Semantic proximity Read ↗

Multiple myeloma clonal evolution in homogeneously treated patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.